PATENT CLAIM ANALYSIS

Application Number: 15934526
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["530", "387100"]

Abstract:
This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.

Claim (Index 22):
The method of  claim 20 , wherein said 31.1 epitope is detected in vitro by an assay selected from the group consisting of Western blot, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), \u201csandwich\u201d immunoassays, lateral flow assay, immunoprecipitation assays, precipitation reactions, gel diffusion precipitation reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunohistochemical assays, fluorescent immunoassays, and protein A immunoassays, or is detected in vivo by a method comprising positron emission tomography (PET), CCD low-light monitoring system, x-ray, CT scanning, scintigraphy, photo acoustic imaging, single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), ultrasound, paramagnetic imaging, and endoscopic optical coherence tomography.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 90.0
- Lexical Diversity: 1.375
- Patent Class: 530.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14655982', '12751791', '15510545', '14460871', '11715307']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.714998596136407
- 35 USC 102 Novelty (BERT): 0.5716271388157366
- Combined Prediction Score: 0.70066145040434
- Mean Citation Score: 431.43559000000016
- Max Citation Score: 566.4305
- Similarity Product: 354.8832993280292

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test